← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
New York/R&D/Ctr/Translational Med/Ther
New Rochelle, NY
$6,047,916
Total funding
7
Grants
Funding over time
peak $1.3M · FY2016–25$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,047,916 · 7
By mechanism
R44$5,128,488 · 3
R43$694,386 · 3
R41$225,042 · 1
Investigators at New York/R&D/Ctr/Translational Med/Ther
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
A novel product for tendinopathy treatment$924,366
R44 · FY2020 · AG
A novel product for tendinopathy treatment$831,571
R44 · FY2021 · AG
Exosome drug for tendinopathy$766,269
R44 · FY2024 · AG
miRNA drug for tendinopathy$737,376
R44 · FY2022 · AG
Exosome drug for tendinopathy$719,580
R44 · FY2025 · AG
miRNA drug for tendinopathy$568,966
R44 · FY2023 · AG
miRNA drug for tendinopathy$560,060
R44 · FY2024 · AG
A product for osteoarthritis treatment and prevention$243,994
R43 · FY2016 · AT
Gene and Stem Cell-Based Treatment for Tendinopathy$225,392
R43 · FY2018 · AG
A novel product for tendinopathy treatment$225,042
R41 · FY2017 · AG
A novel nutraceutical drug for tendinopathy treatment$225,000
R43 · FY2018 · AT
A novel product for tendinopathy treatment$20,300
R44 · FY2021 · AG